Granted Patent B2

US 12,595,495 · App. 18/595,947 · Granted Apr 7, 2026

Inventors: Andreas W. Schirmer (San Diego, CA); Haibo Wang (San Diego, CA); Stephen B. Del Cardayre (San Diego, CA); Zhihao Hu (San Diego, CA); Louis G. Hom (San Diego, CA); Baolong Zhu (San Diego, CA); Cindy Chang (San Diego, CA); Emanuela E. Popova (San Diego, CA)

Assignee: Genomatica, Inc.

C12P7/6409C12N9/0006C12N9/0008C12N9/0071C12N9/0077C12N15/52C12N15/62C12P7/18C12P7/42C12P7/6436C12Y114/14001C12Y114/15003C07K2319/00C12Y101/00C12Y102/01042Y02E50/10

Abstract

Claims (33)

1 . A modified ω-hydroxylase of EC 1.14.15.3, comprising a modified CYP153A polypeptide having at least 90% sequence identity to SEQ ID NO:4, wherein the modified ω-hydroxylase comprises at least one mutation at an amino acid position corresponding to one or more of positions 6, 11, 27, 40, 41, 82, 116, 129, 131, 132, 134, 136, 138, 141, 142, 144, 149, 153, 154, 157, 161, 168, 178, 205, 228, 231, 233, 258, 271, 304, 308, 309, 407, 415, and 419 of SEQ ID NO:4.

2 . The modified ω-hydroxylase of claim 1 , wherein the at least one mutation corresponds to one or more of R6F, I11C, R27L, R40H, K41V, R82D, F116R, Q129R, I131L, L132T, D134G, P136T, P136C, G138F, V141Q, V141G, V141I, V141T, V141M, V141L, E142Q, E142R, F144R, P149R, D153G, V154A, S157V, G161P, G161A, L168V, R178N, R205L, M228R, A231T, S233R, S233N, R258Y, E271F, L304W, G308W, N309R, N309S, N407A, V415R, and M419V.

3 . A modified CYP153A-reductase hybrid fusion polypeptide comprising the modified CYP153A polypeptide of claim 1 fused to a reductase domain.

4 . The modified ω-hydroxylase of claim 3 , wherein the modified CYP153A-reductase hybrid fusion polypeptide has at least 90% sequence identity to SEQ ID NO: 6.

5 . The modified ω-hydroxylase of claim 4 , wherein the modified CYP153A-reductase hybrid fusion polypeptide has a mutation at an amino acid position corresponding to one or more of positions 516, 666, 696, and 796 of SEQ ID NO:6.

6 . The modified ω-hydroxylase of claim 5 , wherein the modified CYP153A-reductase hybrid fusion polypeptide has a mutation corresponding to one or more of T516G, T516V, T516E, P666A, P666H, P666D, P666M, P666K, V696K, V696T, and A796V.

7 . A recombinant microorganism, comprising the modified CYP153A-reductase hybrid fusion polypeptide of claim 3 .

8 . A method of producing an ω-hydroxy fatty acid or derivative thereof, the method comprising culturing the recombinant microorganism of claim 7 in a carbon source, and optionally isolating the ω-hydroxy fatty acid or derivative thereof.

9 . A recombinant microorganism, comprising the modified ω-hydroxylase of claim 1 .

10 . A cell culture, comprising the recombinant microorganism of claim 9 .

11 . A method of producing an ω-hydroxy fatty acid or derivative thereof, the method comprising culturing the recombinant microorganism of claim 9 in a carbon source, and optionally isolating the ω-hydroxy fatty acid or derivative thereof.

12 . A CYP153A-reductase hybrid fusion polypeptide variant, comprising at least 90% sequence identity to SEQ ID NO:6 and comprising at least one mutation at an amino acid position corresponding to one or more of positions 6, 11, 27, 40, 41, 82, 116, 129, 131, 132, 134, 136, 138, 141, 142, 144, 149, 153, 154, 157, 161, 168, 178, 205, 228, 231, 233, 258, 271, 304, 308, 309, 407, 415, 419, 516, 666, 696, and 796, wherein the CYP153A-reductase hybrid fusion polypeptide variant catalyzes the conversion of a fatty acid or derivative thereof to an ω-hydroxy fatty acid or derivative thereof.

13 . The CYP153A-reductase hybrid fusion polypeptide variant of claim 12 , comprising at least one mutation corresponding to R6F, I11C, R27L, R40H, K41V, R82D, F116R, Q129R, I131L, L132T, D134G, P136T, P136C, G138F, V141I, V141T, V141Q, V141G, V141M, V141L, E142R, E142Q, F144R, P149R, D153G, V154A, S157V, G161P, G161A, L168V, R178N, R205L, M228R, A231T, S233R, S233N, R258Y, E271F, L304W, G308W, N309R, N309S, N407A, V415R, M419V, T516E, T516G, T516V, P666A, P666D, P666K, P666H, P666M, V696K, V696T, or A796V, with reference to SEQ ID NO: 6.

14 . A recombinant microorganism, comprising the CYP153A-reductase hybrid fusion polypeptide variant of claim 13 .

15 . A method of producing an ω-hydroxy fatty acid or derivative thereof, the method comprising culturing the recombinant microorganism of claim 14 , and optionally isolating the ω-hydroxy fatty acid or derivative thereof.

16 . A recombinant microorganism, comprising the CYP153A-reductase hybrid fusion polypeptide variant of claim 12 .

17 . The recombinant microorganism of claim 16 , wherein:

the recombinant microorganism produces an ω-hydroxy fatty acid or a derivative thereof;

the ω-hydroxy fatty acid or derivative thereof is an ω-hydroxy free fatty acid; an ω-hydroxy fatty acid ester; an ω-oxo fatty acid; an ω-oxo fatty acid ester; an α,ω-diacid; an ω-carboxy fatty acid ester; an α,ω-diester; an α,ω-diol; an ω-amino fatty acid; an ω-amino fatty acid ester; or a combination thereof; and

the ω-hydroxy fatty acid or derivative thereof is one or more of a saturated or unsaturated C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, or C20 ω-hydroxy fatty acid or derivative thereof; and

wherein the recombinant microorganism optionally further expresses a thioesterase, or an ester synthase, or a combination thereof.

18 . The recombinant microorganism of claim 16 , wherein the recombinant microorganism optionally further expresses a thioesterase, or an ester synthase, or a combination thereof, and wherein the recombinant microorganism further expresses:

(a) an alcohol dehydrogenase or an alcohol oxidase, wherein the recombinant microorganism produces an ω-hydroxy fatty acid derivative that is an ω-oxo fatty acid, an ω-oxo fatty acid ester, or a combination thereof;

(b) an alcohol dehydrogenase or an alcohol oxidase, and an aldehyde dehydrogenase or an aldehyde oxidase, wherein the recombinant microorganism produces an ω-hydroxy fatty acid derivative that is an α,ω-diacid, an ω-carboxy fatty acid ester, or a combination thereof;

(c) an alcohol dehydrogenase or an alcohol oxidase, an aldehyde dehydrogenase or an aldehyde oxidase, and an acyl-CoA ligase or an acyl-CoA transferase, wherein the recombinant microorganism produces an ω-hydroxy fatty acid derivative that is an α,ω-diester;

(d) an alcohol dehydrogenase or an alcohol oxidase, and an aminotransferase or an amine dehydrogenase, wherein the recombinant microorganism produces an ω-hydroxy fatty acid derivative that is an ω-amino fatty acid, an ω-amino fatty acid ester, or a combination thereof;

(e) an alcohol dehydrogenase and a carboxylic acid reductase, wherein the recombinant microorganism produces an ω-hydroxy fatty acid derivative that is an α,ω-diol; or

(f) an acyl-ACP reductase and an alcohol dehydrogenase, wherein the recombinant microorganism produces an ω-hydroxy fatty acid derivative that is an α,ω-diol.

19 . A cell culture, comprising the recombinant microorganism of claim 16 .

20 . A method of producing an ω-hydroxy fatty acid or derivative thereof, the method comprising culturing the recombinant microorganism of claim 16 in a carbon source, and optionally isolating the ω-hydroxy fatty acid or derivative thereof.

21 . The method of claim 20 , wherein:

the ω-hydroxy fatty acid or derivative thereof is one or more of a C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, or C19 ω-hydroxy fatty acid or derivative thereof; and

the ω-hydroxy fatty acid or derivative thereof is an ω-hydroxy free fatty acid; an ω-hydroxy fatty acid ester; an ω-oxo fatty acid; an ω-oxo fatty acid ester; an α,ω-diacid; an ω-carboxy fatty acid ester; an α,ω-diester; an α,ω-diol; an ω-amino fatty acid; an ω-amino fatty acid ester; or a combination thereof.

Assignments (5)

Continuity (4)

References Cited (242)